Theralase Technologies (CVE:TLT) Stock Price Up 3.7% – Here’s Why

Shares of Theralase Technologies Inc. (CVE:TLT) were up 3.7% during mid-day trading on Friday . The company traded as high as C$0.28 and last traded at C$0.28. Approximately 108,776 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 217,092 shares. The stock had previously closed at C$0.27.

Theralase Technologies Trading Up 3.7%

The firm’s fifty day moving average price is C$0.26 and its 200-day moving average price is C$0.21. The company has a market cap of C$74.17 million, a price-to-earnings ratio of -15.56 and a beta of -0.29. The company has a debt-to-equity ratio of 29.26, a current ratio of 0.83 and a quick ratio of 3.40.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.